Anticancer effects of co-administration of daunorubicin and resveratrol in MOLT-4, U266 B1 and Raji cell lines

Farmacia

Volumn 64, Issue 1, 2016, Pages 36-42

  Hashemzaei, Mahmoud ^a   Karami, Saeed Pudine ^a   Delaramifar, Amin ^a   Sheidary, Alireza ^a   Tabrizian, Kaveh ^a   Rezaee, Ramin ^b   Shahsavand, Shabnam ^b   Arsene, Andreea Letitia ^c   Tsatsakis, Aristidis Michael ^d   Taghdisi, Seyed Mohammad ^e  

^a ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NORTH KHORASAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY OF CRETE   (Greece)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Annexin V PI; Apoptosis; Daunorubicin; MOLT 4; MTT; Raji; Resveratrol; U266 B1

Indexed keywords

CASPASE 3; CASPASE 7; CELL CYCLE PROTEIN 6; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; PROSTAGLANDIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RESVERATROL; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; LEUKEMIA; MTT ASSAY;

EID: 84959191876     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer research, 2004; 24(5A): 2783-2840.
2. Al-Harthi S.E., Alarabi O.M., Ramadan W.S., Alaama M.N., Al-Kreathy H.M., Damanhouri Z.A., Khan L. M., Osman A.M., Amelioration of doxorubic ininduced cardiotoxicity by resveratrol. Mol. Med. Rep., 2014; 10(3): 1455-1460.
3. Al-Ismail S.A., Parry D.H., Whittaker J.A., Anthracycline cardiotoxicity and acute myelogenous leukaemia. British Medical Journal, 1977; 1(6064): 815-815.
4. Al-Abd A., Mahmoud A., El-Sherbiny G., El-Moselhy M., Nofal S., El-Latif H., El-Eraky W.El-Shemy H., Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell proliferation, 2011; 44(6): 591-601.
5. Apostolou A., Stagos D., Galitsiou E., Spyrou A., Haroutounian S., Portesis N., Trizoglou I., Hayes A.W., Tsatsakis A.M., Kouretas D., Assessment of polyphenolic content, antioxidant activity, protection against ROS-induced DNA damage and anticancer activity of Vitis vinifera stem extracts. Food and Chemical Toxicology, 2013; 61: 60-68.
6. Arafa M.H., Mohammad N.S., Atteia H.H., Abd-Elaziz H.R., Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J. Physiol. Biochem., 2014; 70(3): 701-711.
7. Aziz M.H., Kumar R., Ahmad N., Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). International Journal of Oncology, 2003; 23(1): 17-28.
8. Barry E., Alvarez J.A., Scully R.E., Miller T.L., Lipshultz S.E., Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy, 2007; 8(8): 1039-1058.
9. Benitez D.A., Pozo-Guisado E., Alvarez-Barrientos A., Fernandez-Salguero P.M., Castellón E.A., Mechanisms Involved in Resveratrol-Induced Apoptosis and Cell Cycle Arrest in Prostate Cancer-Derived Cell Lines. Journal of Andrology, 2007; 28(2): 282-293.
10. Billard C., Izard J.C., Roman V., Kern C., Mathiot C., Mentz F., Kolb J.P., Comparative Antiproliferative and Apoptotic Effects of Resveratrol, ε-viniferin and Vine-shots Derived Polyphenols (Vineatrols) on Chronic B Lymphocytic Leukaemia Cells and Normal Human Lymphocytes. Leukaemia & Lymphoma, 2002; 43(10): 1991-2002.
11. Cecchinato V., Chiaramonte R., Nizzardo M., Cristofaro B., Basile A., Sherbet G.V., Comi P., Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochemical Pharmacology, 2007; 74(11): 1568-1574.
12. Chen H., Tuck T., Ji X., Zhou X., Kelly G., Cuerrier A., Zhang J., Quality assessment of Japanese knotweed (Fallopia japonica) grown on Prince Edward Island as a source of resveratrol. J. Agric. Food Chem., 2013; 61(26): 6383-6392.
13. Choi H.Y., Chong S.A., Nam M.J., Resveratrol induces apoptosis in human SK-HEP-1 hepatic cancer cells. Cancer Genomics-Proteomics, 2009; 6(5): 263-268.
14. Collins I., Garrett M.D., Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Current opinion in pharmacology, 2005; 5(4), 366-373.
15. Dörrie J., Gerauer H., Wachter Y., Zunino S.J., Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukaemia cells. Cancer Research, 2001; 61(12): 4731-4739.
16. Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., Aggarwal B.B., Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NFkappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukaemia cells. Blood, 2003; 102(3): 987-995.
17. Ferrans V.J., Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat. Rep., 1978; 62(6): 955-961.
18. Gali-Muhtasib H., Bakkar N., Modulating cell cycle: current applications and prospects for future drug development. Current cancer drug targets, 2002; 2(4): 309-336.
19. Garvin S., Öllinger K., Dabrosin C., Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters, 2006; 231(1): 113-122.
20. Harper C.E., Cook L.M., Patel B.B., Wang J., Eltoum I.A., Arabshahi A., Shirai T., Lamartiniere C.A., Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. The Prostate, 2009; 69(15): 1668-1682.
21. Hintzpeter J., Hornung J., Ebert B., Martin H.J., Maser E., Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase-Carbonyl reductase 1. Chem. Biol. Interact., 2015; 234: 162-168.
22. Khan G., Haque S.E., Anwer T., Ahsan M.N., Safhi M.M., Alam M.F., Cardioprotective effect of green tea extract on doxorubicin-induced cardiotoxicity in rats. Acta Pol Pharm, 2014; 71(5): 861-868.
23. Kimura Y., Sumiyoshi M., Baba K., Antitumour activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Science, 2008; 99(10): 2083-2096.
24. Kundu J.K., Surh Y.J., Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Letters, 2008; 269(2): 243-261.
25. Leone S., Basso E., Polticelli F., Cozzi R., Resveratrol acts as a topoisomerase II poison in human glioma cells. Int. J. Cancer, 2012; 131(3): E173-178.
26. Li L., Henry G.E., Seeram N.P., Identification and bioactivities of resveratrol oligomers and flavonoids from Carex folliculata seeds. Journal of agricultural and food chemistry, 2009; 57(16): 7282-7287.
27. Liang X., Yang D., Hu J., Hao X., Gao J., MAO Z., Hypoxia inducible factor-1alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer research, 2008; 28(3A): 1659-1666.
28. Liang Y.C., Tsai S.H., Chen L., Lin-Shiau S.Y., Lin J.K., Resveratrol-induced G 2 arrest through the inhibition of CDK7 and p34 CDC2 kinases in colon carcinoma HT29 cells. Biochemical Pharmacology, 2003; 65(7): 1053-1060.
29. Lippman M., Zager R., Henderson E.S., High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukaemia. Cancer Chemother. Rep., 1972; 56(6): 755-760.
30. Luther D.J., Ohanyan V., Shamhart P.E., Hodnichak C.M., Sisakian H., Booth T.D., Meszaros J.G., Bishayee A., Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Investigational new drugs, 2011; 29(2): 380-391.
31. Mann J.R., Backlund M.G., DuBois R.N., Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol., 2005; 2(4): 202-210.
32. Margină D., Ilie M., Grădinaru D., Androutsopoulos V.P., Kouretas D., Tsatsakis A.M., Natural products-friends or foes? Toxicology Letters, 2015; 236(3): 154-167.
33. Melillo G., Targeting hypoxia cell signaling for cancer therapy. Cancer and Metastasis Reviews, 2007; 26(2): 341-352.
34. Notas G., Nifli A.P., Kampa M., Vercauteren J., Kouroumalis E., Castanas E., Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochimica et Biophysica Acta (BBA)-General Subjects, 2006; 1760(11): 1657-1666.
35. Olaru O.T., Venables L., van de Venter M., Nitulescu G.M., Margina D., Spandidos D.A., Tsatsakis A.M., Anticancer potential of selected Fallopia Adans species. Oncology Letters, 2015; 10(3): 1323-1332.
36. Park S.Y., Jeong K.J., Lee J., Yoon D.S., Choi W.S., Kim Y.K., Han J.W., Kim Y.M., Kim B.K., Lee H.Y., Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett, 2007; 258(1): 63-69.
37. Puissant A., Auberger P., AMPK-and p62/SQSTM1-dependent autophagy mediate Resveratrol-induced cell death in chronic myelogenous leukaemia. Autophagy, 2010; 6(5): 655-657.
38. Rezaee R., Mahmoudi M., Abnous K., Zamani Taghizadeh Rabe S., Tabasi N., Hashemzaei M., Karimi G., Cytotoxic effects of crocin on MOLT-4 human leukaemia cells. Journal of Complementary and Integrative Medicine, 2013; 10(1): 105-112.
39. Roman V., Billard C., Kern C., Ferry-Dumazet H., Izard J.C., Mohammad R., Mossalayi D.M., Kolb J.P., Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. British Journal of Haematology, 2002; 117(4): 842-851.
40. Scalbert A., Williamson G., Dietary intake and bioavailability of polyphenols. J. Nutr., 2000; 130(8): 2073S-2085S.
41. Schroeter A., Marko D., Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells. Molecules, 2014; 19(12): 20054-20072.
42. Sheu M.T., Jhan H.J., Hsieh C.M., Wang C.J., Ho H.O., Efficacy of Antioxidants as a Complementary and Alternative Medicine (CAM) in Combination With the Chemotherapeutic Agent Doxorubicin. Integr. Cancer Ther., 2015; 14(2): 184-195.
43. Sin T.K., Tam B.T., Yung B.Y., Yip S.P., Chan L.W., Wong C.S., Ying M., Rudd J.A., Siu P.M., Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J. Physiol., 2015; 593(8): 1887-1899.
44. Stagos D., Portesis N., Spanou C., Mossialos D., Aligiannis N., Chaita E., Panagoulis C., Reri E., Skaltsounis L., Tsatsakis A.M., Correlation of total polyphenolic content with antioxidant and antibacterial activity of 24 extracts from Greek domestic Lamiaceae species. Food and Chemical Toxicology, 2012; 50(11): 4115-4124.
45. Tsan M.F., White J.E., Maheshwari J.G., Bremner T.A., Sacco J., Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. British Journal of Haematology, 2000; 109(2): 405-412.
46. Türedi S., Yuluğ E., Alver A., Kutlu Ö., Kahraman C., Effects of resveratrol on doxorubicin induced testicular damage in rats. Experimental and Toxicologic Pathology, 2015; 67(3): 229-235.
47. Vejpongsa P., Yeh E.T.H., Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. Journal of the American College of Cardiology, 2014; 64(9): 938-945.
48. Wieder T., Prokop A., Bagci B., Essmann F., Bernicke D., Schulze-Osthoff K., Dorken B., Schmalz H., Daniel P., Henze G., Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukaemia, 2001; 15(11): 1735-1742.
49. Woodcock T.M., Allegra J.C., Richman S.P., Lalley K., Kubota T.T., Blumenreich M.S., Gentile P., Jones M., Seeger J., Pharmacology and phase I clinical studies of daunorubicin in patients with advanced malignancies. Semin. Oncol., 1984; 11(4 Suppl 3): 28-32.
50. Zordoky B.N.M., Robertson I.M., Dyck J.R.B., Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2015; 1852(6): 1155-1177.